Amphastar Pharmaceuticals 

$19.84
284
-$0.25-1.24% 今天

統計

當日最高
20.43
當日最低
19.59
52週高點
31.26
52週低點
16.65
成交量
41,308,667
平均成交量
-
市值
900.14M
本益比
12.1
股息殖利率
-
股息
-

即將到來

財報

10Aug預期
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
下一步
0.42
0.61
0.8
0.99
預期EPS
0.638429
實際EPS
不適用

財務

13.63%利潤率
有盈利
2020
2021
2022
2023
2024
2025
1.44B營收
196.19M淨利

分析師評級

20.50平均目標價
最高預估為 22.00。
來自過去6個月內的 5 則評分。這不是投資建議。
買入
0%
持有
100%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 AMPH 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Show more...
執行長
Dr. Ziping Luo Ph.D.
員工
2028
國家
美國
ISIN
US03209R1032

上市

0 Comments

分享你的想法

FAQ

Amphastar Pharmaceuticals 今天的股價是多少?
AMPH 目前價格為 $19.84 USD,過去 24 小時下跌了 -1.24%。在圖表上更密切關注 Amphastar Pharmaceuticals 股票的表現。
Amphastar Pharmaceuticals 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Amphastar Pharmaceuticals 的股票以代號 AMPH 進行交易。
Amphastar Pharmaceuticals 的股價在上漲嗎?
AMPH 股票較上週上漲 +2.22%,本月上漲 +17.49%,但過去一年 Amphastar Pharmaceuticals 下跌 -23.24%。
Amphastar Pharmaceuticals 的市值是多少?
今天 Amphastar Pharmaceuticals 的市值為 900.14M
Amphastar Pharmaceuticals 下一次財報日期是什麼時候?
Amphastar Pharmaceuticals 將於 August 10, 2026 公布下一次財報。
Amphastar Pharmaceuticals 上一季度的財報如何?
AMPH 上一季度的財報為每股 0.42 USD,預估為 0.71 USD,帶來 -40.44% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Amphastar Pharmaceuticals 去年的營收是多少?
Amphastar Pharmaceuticals 去年的營收為 1.44BUSD。
Amphastar Pharmaceuticals 去年的淨利是多少?
AMPH 去年的淨收益為 196.19MUSD。
Amphastar Pharmaceuticals 有多少名員工?
截至 June 15, 2026,公司共有 2,028 名員工。
Amphastar Pharmaceuticals 位於哪個產業?
Amphastar Pharmaceuticals從事於Health & Wellness產業。
Amphastar Pharmaceuticals 何時完成拆股?
Amphastar Pharmaceuticals 最近沒有進行任何拆股。
Amphastar Pharmaceuticals 的總部在哪裡?
Amphastar Pharmaceuticals 的總部位於 美國 的 Rancho Cucamonga。